Oarsman Capital Inc. Purchases New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 1,317 shares of the company’s stock, valued at approximately $29,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 24.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company’s stock worth $16,203,000 after acquiring an additional 177,836 shares during the period. Captrust Financial Advisors grew its holdings in Teva Pharmaceutical Industries by 48.4% in the 3rd quarter. Captrust Financial Advisors now owns 15,786 shares of the company’s stock valued at $284,000 after buying an additional 5,146 shares in the last quarter. HighTower Advisors LLC increased its position in Teva Pharmaceutical Industries by 461.8% during the 3rd quarter. HighTower Advisors LLC now owns 148,605 shares of the company’s stock worth $2,675,000 after buying an additional 122,154 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Teva Pharmaceutical Industries by 34.5% during the third quarter. Quantinno Capital Management LP now owns 36,145 shares of the company’s stock worth $651,000 after buying an additional 9,269 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TEVA shares. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Friday. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Down 6.9 %

Shares of TEVA stock opened at $13.83 on Monday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The company has a market cap of $15.68 billion, a PE ratio of -9.54, a P/E/G ratio of 1.44 and a beta of 0.82. The stock’s fifty day moving average price is $16.52 and its two-hundred day moving average price is $18.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.